The company plans on using the solution as an interventional radiology treatment for men’s prostates, to shrink uterine fibroid tumors and in coordination with chemotherapy. The company will use the solution as a platform for future products. EmboMedics plans to have submitted its first generation device for 510(k) clearance by the end of 2014, according to the report.
More Articles on Supply Chain:
Medline Launches New Products Catalog
Boston Scientific Looks to Expand Chinese Presence
Supply Chain Efficiency Improved With Inventory Management Intervention
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
